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Background: The use of topical antimicrobial agents for management of minor skin infections is a clinical
strategy that is commonly practiced in the community. Coupled with the use of topical antimicrobialKey words:
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agents is the emergence of antibiotic-resistant strains of pathogens leading to the need for alternative
treatments.
Objective: A novel topical combination ointment consisting of salicylic acid, oak bark extract, benzoic
acid, and polyethylene glycol (Bensal HP, Sonar products Inc., Carlstadt, NJ) with antimicrobial properties
was assessed to determine its spectrum of activity.
Methods: One hundred eighty-four bacterial and fungal isolates from culture collections that included
multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa,
Acinetobacter spp, and gram-negative so-called superbugs, as well as yeasts and ﬁlamentous fungi, were
investigated by cylinder diffusion and agar dilution assays.
Results: All 184 bacterial and fungal isolates were susceptible to the combination ointment at the clinically
applied concentration and there was no evidence of cross-resistance between Bensal HP and other classes
of antimicrobials. In time-kill tests, Bensal HP was rapidly bactericidal against P aeruginosa ATCC 27853 and
methicillin-resistant S aureus SA179 at 4  the MIC, a concentration that is applied clinically.
Conclusions: The results of this study suggest that this combination ointment has a broad in vitro spectrum
of antimicrobial activity against both more common bacterial and fungal pathogens and may be
particularly useful for treatment of infections by multidrug-resistant organisms. Additional studies are
warranted to investigate the full clinical utility as a therapeutic agent and also for possible infection control
interventions.
& 2016. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Antibiotic resistance is a serious health threat and has the potential
for dire consequences. The Centers for Disease Control and PreventionInc. This is an open access article u
entral Association of Clinical
well as the 114th General
, May 20, 2014, Boston,
, PhD, Department of Pathol-
le School of Medicine, 530 S
K.S. Thomson).
.estimate that more than 2 million individuals in the United States
develop illness resulting from antibiotic-resistant infections on an
annual basis and published Antibiotic Resistance Threats in the United
States, 2013,1 which provides a snapshot of the complex problem of
antibiotic resistance. The threats were prioritized as urgent, serious,
and concerning. Of particular concern is increasing multidrug resist-
ance coupled with cessation of antibiotic discovery programs by most
major pharmaceutical companies. This situation has created a major
global health crisis inwhich there are few or no effective agents to treat
common bacterial infections or infections caused by less common
pathogens, including Mycobacterium spp,2,3 ﬁlamentous fungi, and
yeasts.4–6 Furthermore, alternative second- and third-line agents that
are effective are also associated with safety issues. Most current
concerns about antibiotic resistance focus on infections in hospitalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table I
Summary of cylinder test zone sizes for test isolates.
Organism No.
tested
Range of zone
(mm)
Drug-sensitive
zone*
Escherichia coli (M) 17 11–16 12
Klebsiella pneumoniae (M) 13 12–18 13
Serratia marcescens (M) 10 13–19 13
Pseudomonas aeruginosa (M) 11 13–18 13
Acinetobacter baumannii (M) 13 14–18 16
Methicillin-sensitive Staphylococcus
aureus
12 16–23 16
Methicillin-resistant Staphylococcus
aureus (M)
11 20–22
Enterococcus faecalis (M) 11 16–21 17
Streptococcus pyogenes 12 10–15 0
Nocardia brasiliensis 10 18–42 0
Mycobacterium fortuitum 10 22–36 0
Candida albicans 10 14–19 0
Candida glabrata 10 12–17 0
Trichophyton rubrum 12 21–31 0
Trichophyton tonsurans 10 18–37 0
Trichophyton mentagrophytes 10 22–27 0
Propionibacterium acnes 1 27 0
Cryptococcus neoformans 1 18 0
Total 184
M ¼ multidrug-resistant organisms included.
n Zone of 0 mm indicates resistant. Note that zones for drug-sensitive isolates
of Escherichia coli, K pneumoniae, Serratia marcescens, Pseudomonas aeruginosa, and
Enterococcus faecalis tended to be smaller (suggesting they were more resistant)
than those of their multidrug-resistant counterparts.
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of topical agents against multidrug-resistant organisms (MDROs), some
of which are likely to be compromised because they contain agents
to which resistance has already been reported. These include
neomycin, polymyxin B, bacitracin, and mupirocin.7,8 Bensal HP
(Sonar Products Inc., Carlstadt, NJ) is a combination topical ointment
with antimicrobial properties with activity against methicillin-resistant
Staphylococcus aureus (MRSA) and common bacterial and fungal
skin pathogens.9–11 The current study was designed to assess
the in vitro activity of Bensal HP against a broad range of contemporary
pathogens, including MDROs such as MRSA, vancomycin-resistant
Enterococcus, gram-negative so-called superbugs,Mycobacterium fortu-
itum, Nocardia brasiliensis, yeasts, and ﬁlamentous fungi.Materials and Methods
Test agent
Bensal HP contains salicylic acid (30 mg/g), benzoic acid (60
mg/g), QRB-7 (oak bark extract) (30 mg/g), and vehicle poly-
ethylene glycol 400 and polyethylene glycol 3350. The test agent
was provided by SMG Pharmaceuticals, Cary, North Carolina.
Organisms
In vitro activity was investigated against 184 bacterial and
fungal isolates from the culture collections of Creighton University,
Omaha, Nebraska; the Alegent Creighton Hospital Microbiology
Laboratory, Omaha, Nebraska; and the University of Louisville
Hospital Microbiology Laboratory, Louisville, Kentucky. The bacte-
rial isolates were from US and international sources and included
well characterized non-MDRO and MDRO isolates of Enterobacter-
iaceae (n ¼ 40), Pseudomonas aeruginosa (n ¼ 11); Acinetobacter
baumannii (n ¼ 13); S aureus (n ¼ 23), including MRSA
and methicillin-susceptible S aureus; and Enterococcus faecalis
(n ¼ 11), including vancomycin-resistant Enterococcus, Group AStreptococcus (Streptococcus pyogenes [n ¼ 12]), Propionibacterium
acnes (n ¼ 1), M fortuitum (n ¼ 10), and N brasiliensis (n ¼ 10).
The fungal isolates were Candida albicans (n ¼ 10), Candida
glabrata (n ¼ 10), Cryptococcus neoformans (n ¼ 1), Trichophyton
rubrum (n ¼ 12), T tonsurans (n ¼ 10), and T mentagrophytes
(n ¼ 10). The gram-negative bacteria were previously character-
ized for resistance mechanisms by phenotypic, biochemical, and
molecular methods.2 These included isolates of Enterobacteria-
ceae, Pseudomonas spp, and Acinetobacter spp producing the
extended spectrum β-lactamases TEM-52, SHV-4, SHV-12,
OXA-45, CTX-M-1, CTX-M-9, CTX-M-12, CTX-M-14, CTX-M-15,
CTX-M-17, CTX-M-18, and CTX-M-19; chromosomal and plasmid-
mediated AmpC β-lactamases, including FOX-like and CMY-2
enzymes; and carbapenemases of the IMP, VIM, KPC, OXA, and
NDM families. The Pseudomonas aeruginosa isolates included some
with upregulated MexAB, MexEF, and MexXY efﬂux pumps, and
downregulation of the OprD porin. The isolates included organ-
isms described in the media as superbugs because of their
resistance to most available antibacterial agents. ATCC reference
isolates included in the study were Escherichia coli ATCC 25922,
Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853,
Staphylococcus aureus ATCC 25923, Staphylococcus aureus ATCC
29213, Enterococcus faecalis ATCC 29212, and T mentagrophytes
ATCC 9533.
Cylinder diffusion susceptibility testing
All isolates were tested by a cylinder diffusion procedure12,13
that was a modiﬁcation of the Clinical and Laboratory Standards
Institute (CLSI) disk diffusion method.14,15 In this procedure a
cylinder containing Bensal HP was substituted for the impregnated
ﬁlter paper disks of the CLSI method. Bensal HP liqueﬁed by
heating to 56oC for 10 minutes and 40 μL was pipetted into a
sterile metal cylinder placed on a lawn culture of the test
organism. The lawn culture of the test isolate was prepared
according to CLSI methodology and inoculated onto appropriate
media (see Media). The tests with gram-negative pathogens,
staphylococci, streptococci, and enterococci were incubated as
recommended by CLSI; that is, overnight, typically 18–20 hours.
All other isolates were incubated for as long as necessary to be able
to visualize sufﬁcient growth to allow measurement of an inhib-
ition zone; that is, 48–72 hours. After incubation, inhibition
diameters around the cylinders were measured and recorded
according to the CLSI method. In the absence of CLSI interpretive
criteria, any zone of inhibition was interpreted to indicate suscept-
ibility and the absence of an inhibition zone indicated resistance.
This interpretation was adopted to correlate with the occurrence
or absence of activity at the undiluted concentration of Bensal HP
that is used therapeutically.
MIC testing
Bensal HP MICs were determined by CLSI agar dilution method-
ology.14,15 The test isolates were 73 representative bacterial
isolates that were capable of overnight growth at 35oC on
Mueller-Hinton agar.
Time-kill testing
Using concentrations based on the agar dilution MICs, the
bactericidal activity of Bensal HP against Pseudomonas aeruginosa
ATCC 27853 and MRSA SA179 was determined by time-kill
methodology. The Bensal HP concentrations tested were 4  the
MIC and 1  the MIC. Drug-free and antibiotic-supplemented
Mueller-Hinton broths were inoculated to provide an initial
inoculum of Z5  105 CFU/mL of each isolate. Growth rates
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4, and 24 hours. Samples for the counts were plated on Roswell
Park Memorial Institute (RPMI) 1640 medium (Remel, Lenexa,
Kansas). This medium inhibits Bensal HP activity and is therefore
suitable to inactivate drug carryover in the samples. Bactericidal
activity was interpreted as Z3 log10 CFU/mL decrease after 24
hours of incubation.
Media
Susceptibility tests were performed on Mueller-Hinton agar
(BD Diagnostic Systems, Sparks, Maryland) exception for micro-
organisms that did not grow well on this medium. Group A
streptococci were tested on Mueller-Hinton agar supplemented
with 5% sheep’s blood (BD Diagnostic Systems), and fungal isolates
were tested on Sabouraud dextrose agar (Remel). Initial tests of
antifungal activity with RPMI 1640 medium determined that this
medium antagonized the activity of Bensal HP and was unsuitable
for susceptibility testing. Time-kill testing was performed in
Mueller-Hinton broth (BD Diagnostic Systems) with viable counts
determined on RPMI 1640 medium.Results
All 184 bacterial and fungal isolates were susceptible to this
combination ointment in the cylinder diffusion tests. No resistance
was detected. The susceptibility of both wild type and MDRO
isolates indicated that the mechanisms of resistance to other
antimicrobial agents of the isolates did not compromise Bensal
HP activity. Inhibition zone diameters were generally larger for
gram-positive bacteria and ﬁlamentous fungi than for gram-
negative bacteria (Table I). Curiously, some MDROs had larger
inhibition zones than their wild type counterparts (Table I).
Figure 1 shows 3 cylinder tests on 1 plate in which isolates of
MRSA, Escherichia coli, and Pseudomonas aeruginosawere inhibited
by this combination ointment.
The 73 isolates in the MIC tests included both MDROs and non-
MDROs for each species tested. All gram-positive isolates were
inhibited by an 80-fold dilution of Bensal HP, which correspondedMRSA
E. coli Pseudomonas
aeruginosa
Figure 1. Three cylinder tests showing inhibition of methicillin-resistant Staphy-
lococcus aureus (MRSA), Escherichia coli (E. coli), and Pseudomonas aeruginosa on
Mueller-Hinton agar after diffusion of Bensal HP (Sonar Products Inc., Carlstadt, NJ)
from cylinders.to salicylic acid/benzoic acid/QRB-7 concentrations of 0.375/0.75/
0.375 mg/g, respectively; that is, identical MIC50 and MIC90 values
of 80-fold dilution of Bensal HP. The gram-negative isolates
were all susceptible to a 40-fold dilution of Bensal HP (0.75/1.5/
0.75 mg/g), whereas MIC50 and MIC90 values were 80-fold and 40-
fold dilutions, respectively.
In time-kill tests, the combination ointment was rapidly bac-
tericidal against Pseudomonas aeruginosa ATCC 27853 and MRSA
SA179 at 4  MIC. This concentration was a 20-fold dilution of the
concentration that is applied clinically. No regrowth occurred
during the 24-hour incubation period. The Pseudomonas aerugi-
nosa isolate was killed very rapidly. The initial count of Z2  106
CFU/mL was reduced to 800 CFU/mL by the time the inoculumwas
sampled and plated for the time zero reading. That is, the
bactericidal criterion of at least a 3-log reduction in viable count
was achieved within approximately 5 minutes of exposure to
Bensal HP. The MRSA isolate was killed with a 44 log kill attained
within an hour of exposure to 4  MIC. At 1  MIC (ie, an 80-fold
dilution of the clinical concentration) the viable counts were
unchanged after 24 hours. On sampling the tests after 24 hours,
there was no evidence of reduced susceptibility to Bensal HP in
cylinder diffusion; that is, mutational resistance did not emerge
during prolonged exposure to Bensal HP.
Bensal HP was active against 10 isolates each of Candida
albicans and Candida glabrata when tested on Sabouraud agar
but was inactive against both species on RPMI 1640 medium. This
indicated that RPMI 1640 medium antagonized the activity of
Bensal HP and susceptibility tests on RPMI 1640 medium were
discontinued. On Sabouraud agar, Bensal HP was also active
against 12 isolates of T rubrum, 10 isolates of T tonsurans, 10
isolates of T mentagrophytes, and a single isolate of Cryptococcus
neoformans. Figures 2 and 3 show the inhibition of Candida
albicans and T mentagrophytes, respectively, by Bensal HP.Discussion
Bensal HP is currently marketed and is indicated for treatment
of the inﬂammation and irritation associated with many common
forms of dermatitis, including certain eczematous conditions.
These conditions include complications associated with pyoder-
mas. It is also used for the treatment of insect bites, burns,Candida
albicans 5
Figure 2. Inhibition of Candida albicans on Sabouraud agar by Bensal HP (Sonar
Products Inc., Carlstadt, NJ).
Trichophyton
mentagrophytes 3
Figure 3. Inhibition of Trichophyton mentagrophytes on Sabouraud agar by
Bensal HP (Sonar Products Inc., Carlstadt, NJ).
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reepithelialization.10
This study conﬁrmed and extended previous information about
the in vitro antimicrobial spectrum of Bensal HP.10 The most
important ﬁnding was that all 184 bacteria, yeasts, and ﬁlamen-
tous fungi tested were susceptible to the clinically used concen-
tration of Bensal HP, indicating that it has a very broad spectrum of
activity compared with other topical agents. In addition, the
ﬁnding that Bensal HP was not compromised by mechanisms of
antibiotic cross-resistance between it and other classes of anti-
microbials is of interest.
Of note, multidrug-resistant Acinetobacter, extended spectrum
β-lactamase–producing Enterobacteriaceae, multiresistant Pseudo-
monas aeruginosa, and MRSA were inhibited by Bensal HP. These
pathogens correspond to the categories of potential pathogen
threats listed in the Centers for Disease Control and Prevention
report.1 The results from our study suggest that Bensal HP may
provide an effective topical treatment in situations where MDROs
are problematic. Additional study will be needed to substantiate
this clinical utility.
The activity of Bensal HP against M fortuitum also raises the
possibility of activity against otherMycobacterium species, some of
which are highly drug-resistant. In addition, the absence of muta-
tional resistance emerging during prolonged exposure in the time-
kill tests suggested that pathogens may not easily develop resist-
ance to Bensal HP.
Additional investigation is needed on the mechanism of action
of Bensal HP and whether the antimicrobial activity results from
the individual components or whether the combination is required
to demonstrate these effects. Currently, the mechanism of action is
not known.
Further studies are warranted to investigate the potential
prophylactic, decolonization, and therapeutic uses of Bensal HP.
It would also be useful to compare its activity to other topical
agents such as the combinations of bacitracin/neomycin/poly-
myxin, and bacitracin/polymyxin, and the monocomponent
agents, mupirocin, and silver sulfadiazine.
A limitation of this study is that there is neither a standardized
susceptibility test method nor interpretative criteria for topical
ointments such as Bensal HP, with the exception of mupirocin,which is water-soluble.16 In the absence of such methodology, the
cylinder test method using the clinically applied concentration
provided useful information.Conclusions
Bensal HP is a very-broad-spectrum topical antimicrobial agent
with in vitro activity against important pathogens such as MRSA,
Pseudomonas aeruginosa, gram-negative superbugs, yeasts, and
ﬁlamentous fungi. Based on the in vitro ﬁndings in this study,
additional studies are warranted to better understand the full
clinical utility of this agent.Acknowledgments
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